Phase
Condition
Multiple Myeloma
Vomiting
Lactose Intolerance
Treatment
Olanzapine
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Receipt of high-dose melphalan 140-200 mg/m2
Autologous stem cell transplantation recipient
Exclusion
Exclusion Criteria:
Allergy to olanzapine
Documented nausea or vomiting within 24 hours prior to enrollment
Treatment with other antipsychotic agents such as risperidone, quetiapine,clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment orplanned during protocol therapy
Chronic alcoholism
Pregnant
Decline or unable to provide informed consent
Study Design
Study Description
Connect with a study center
Wellstar MCG
Augusta, Georgia 30912
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.